Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
pelacarsen - ASO targeting Lp(a)
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04023552 Lp(a) HORIZON (CTQJ230A12301)
Cardiovascular risk reduction
Phase 3
7680
Time to the first occurrence of MACE (cardiovascular death, non-fatal MI, non-fatal
stroke and urgent coronary re-vascularization)
TQJ230 80 mg injected monthly subcutaneously or matched placebo
Patients with a history of Myocardial infarction or Ischemic Stroke, or a clinically
significant symptomatic Peripheral Artery Disease, and Lp(a) >= 70 mg/dL
Target Patients
Read-out Milestone(s)
2025
Publication
TBD
76 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation